Dataset Information

Detection of Five Solid Carcinomas Using Blood Circulating Proteins

ABSTRACT: When diagnosed in a metastatic stage cancer is mostly incurable making its early detection via biomarkers of immense clinical interest. Proteins circulating in blood are a preferred source of biomarkers for a wide range of cancers due to the ease and non-invasiveness of collection. Our approach to cancer biomarker discovery is based on the observation that proteomic changes in tumor tissue are remotely detectable as changes in the protein composition of blood plasma. To determine whether these changes in the plasma of patients are specific for their specific cancer or represent a response to cancer in general we performed a cross-tumor plasma proteomic study. Using a proteomic serum/plasma workflow consisting of the combined use of N-glycosite enrichment and SWATH mass spectrometry (SWATH-MS), we investigated 155 blood samples derived from cohorts of patients with carcinomas at a localized or locally advanced clinical stage, or from a matched control group. A quantitative comparison of the resulting N-glycosite profiles indicated that some biomarkers are common to several cancers, while others are highly specific for one cancer type.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Blood Serum

DISEASE(S): Lung Cancer,Prostate Adenocarcinoma,Colon Cancer,Pancreatic Cancer,Malignant Neoplasm Of Ovary

SUBMITTER: Tatjana Sajic

LAB HEAD: Ruedi Aebersold

PROVIDER: PXD004998 | Pride | 2018-08-09

REPOSITORIES: Pride

ACCESS DATA

Publications

Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS.

Sajic Tatjana T Liu Yansheng Y Arvaniti Eirini E Surinova Silvia S Williams Evan G EG Schiess Ralph R Hüttenhain Ruth R Sethi Atul A Pan Sheng S Brentnall Teresa A TA Chen Ru R Blattmann Peter P Friedrich Betty B Niméus Emma E Malander Susanne S Omlin Aurelius A Gillessen Silke S Claassen Manfred M Aebersold Ruedi R

Cell reports 20180501 9

Cancer is mostly incurable when diagnosed at a metastatic stage, making its early detection via blood proteins of immense clinical interest. Proteomic changes in tumor tissue may lead to changes detectable in the protein composition of circulating blood plasma. Using a proteomic workflow combining N-glycosite enrichment and SWATH mass spectrometry, we generate a data resource of 284 blood samples derived from patients with different types of localized-stage carcinomas and from matched controls. ...[more]

PMID: 29847809

Similar Datasets

Project description:Ovarian cancer is one of the most common cancer among women in the world, and chemotherapy remains the principal treatment for patients. However, drug resistance is a major obstacle to the effective treatment of ovarian cancers and the underlying mechanism is not clear. An increased understanding of the mechanisms that underline the pathogenesis of drug resistance is therefore needed to develop novel therapeutics and diagnostic. Herein, we report the comparative analysis of the doxorubicin sensitive OVCAR8 cells and its doxorubicin-resistant variant NCI/ADR-RES cells using integrated global proteomics and N-glycoproteomics. A total of 1525 unique N-glycosite-containing peptides from 740 N-glycoproteins were identified and quantified, of which 253 N-glycosite-containing peptides showed significant change in the NCI/ADR-RES cells. Meanwhile, stable isotope labeling by amino acids in cell culture (SILAC) based comparative proteomic analysis of the two ovarian cancer cells led to the quantification of 5509 proteins. As about 50% of the identified N-glycoproteins are low-abundance membrane proteins, only 44% of quantified unique N-glycosite-containing peptides had corresponding protein expression ratios. The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy. Integrated proteomic and N-glycoproteomic analyses provide new insights, which can help to unravel the relationship of N-glycosylation and multidrug resistance (MDR), understand the mechanism of MDR, and discover the new diagnostic and therapeutic targets.

Project description:Introduction: microRNAs are promising candidate breast cancer biomarkers due to their cancer-specific expression profiles. However, efforts to develop circulating breast cancer biomarkers are challenged by the heterogeneity of microRNAs in the blood. To overcome this challenge, we aimed to develop a molecular profile of microRNAs specifically secreted from breast cancer cells. Our first step towards this direction relates to capturing and analyzing the contents of exosomes, which are small secretory vesicles that selectively encapsulate microRNAs indicative of their cell of origin. To our knowledge, circulating exosome microRNAs have not been well evaluated as biomarkers for breast cancer diagnosis or monitoring. Methods: Exosomes were collected from the conditioned media of human breast cancer cell lines, mouse plasma of patient-derived orthotopic xenograft models (PDX), and human plasma samples. Exosomes were verified by electron microscopy, nanoparticle tracking analysis, and western blot. Cellular and exosome microRNAs from breast cancer cell lines were profiled by next-generation small RNA sequencing. Plasma exosome microRNA expression was analyzed by qRT-PCR analysis. Results: Small RNA sequencing and qRT-PCR analysis showed that several microRNAs are selectively encapsulated or highly enriched in breast cancer exosomes. Importantly, the selectively enriched exosome microRNA, human miR-1246, was detected at significantly higher levels in exosomes isolated from PDX mouse plasma, indicating that tumor exosome microRNAs are released into the circulation and can serve as plasma biomarkers for breast cancer. This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 breast cancer patients as compared to the plasma exosomes of healthy control subjects. Receiver Operating Characteristic (ROC) curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 levels is a better indicator of breast cancer than their individual levels. Conclusions: Our results demonstrate that certain microRNA species, such as miR-21 and miR-1246, are selectively enriched in human breast cancer exosomes and significantly elevated in the plasma of breast cancer patients. These findings indicate a potential new strategy to selectively analyze plasma breast cancer microRNAs indicative of the presence of breast cancer.

Dataset Information

Detection of Five Solid Carcinomas Using Blood Circulating Proteins

Publications

Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure